Compare GSK plc (GSK) vs Manchester United PLC (MANU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Manchester United PLC — how do they compare? GSK plc trades at $46.62 (market cap $91.88B), while Manchester United PLC trades at $20.67 (market cap $3.51B). The key difference: GSK plc is far larger — about 26.2× Manchester United PLC's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Manchester United PLC for 109 Days on average.
| GSK | MANU | |
|---|---|---|
Market Cap | $91.88B | $3.51B |
Volume | 7,730,529 | 412,769 |
Sector | Health | Media |
52-Week High | $61.18 | $24.19 |
52-Week Low | $43.24 | $15.20 |
Typical Hold Time | 93 Days | 109 Days |
Enterprise Value | $111.88B | $4.33B |
Dividend Yield | 3.9% | 1.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
Manchester United (MANU) trades at $20.60, up 1.73% with a bearish technical signal despite recent earnings beats. The company shows mixed fundamentals with revenue growth to $666.51M in 2025 but negative net income margins and ROE. Analyst sentiment is divided with 40% buy ratings, while cash flow trends show heavy investment spending offset by financing activities.
The stock presents a valuation disconnect opportunity with market cap below Forbes' franchise estimates, but faces execution risks from persistent losses and high debt load. Upside depends on Champions League revenue conversion and cost management, while downside risks include sustained profitability challenges in the competitive sports landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →
